Previous 10 | Next 10 |
Editor's note: Seeking Alpha is proud to welcome James Mase as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Thesis Tetra...
JERUSALEM , May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY DEVICE FOR ORAL INTAKE OF AN AGENT," and covers Intec's gastro-retenti...
Iovance Biotherapeutics (NASDAQ: IOVA ) +36% on positive TIL data . More news on: Iovance Biotherapeutics, Inc., CUI Global, Inc., MacroGenics, Inc., Stocks on the move, Read more ...
NEW YORK , May 16, 2019 /PRNewswire/ --Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into an agreement with Merck, known as MSD outside the United States and Canada , to explore using the Accordion Pill ® (AP) platform for an undisclos...
On today’s podcast, we sit down with Dan Ahrens, the portfolio manager of the AdvisorShares Pure Cannabis ETF ( YOLO ), the first actively managed ETF with a dedicated cannabis investment mandate domiciled in the United States. Dan is no stranger to the investing in vice stocks (tobacco...
Intec Pharma (NASDAQ: NTEC ): Q1 GAAP EPS of -$0.32 beats by $0.05. More news on: Intec Pharma Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
JERUSALEM , May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three months ended March 31, 2019 and provides a corporate update. Highlights of the first quarter 2019 and recent weeks include: ...
JERUSALEM , May 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) was accepted...
JERUSALEM , April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the last patient has completed their final visit in the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pi...
JERUSALEM , April 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference. HC Wainwright Global Life Sciences Conference Dat...
News, Short Squeeze, Breakout and More Instantly...
Intec Pharma Ltd. Company Name:
NTEC Stock Symbol:
NASDAQ Market:
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE...